MedTrace Logo

Study of MGTA-145 and Plerixafor in Patients With Sickle Cell Disease

NCT05445128 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 1

Last updated 2025-07-25

Study results available
· View outcomes & findings →

Summary

This research study is designed to investigate a new potential medicine for mobilizing stem cells and apheresis collection in patients with Sickle Cell Disease. MGTA-145, the new potential medicine, will be given with plerixafor.

Conditions

Interventions

BIOLOGICAL

MGTA-145

MGTA-145 will be administered as an IV infusion

DRUG

Plerixafor

240 µg/kg administered subcutaneously

Sponsors & Collaborators

  • Genetix Biotherapeutics Inc.

    collaborator INDUSTRY

  • Ensoma

    lead INDUSTRY

Principal Investigators

  • Ji Hyun Lee, MD, MPH · Magenta Therapeutics

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
35 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-06-24
Primary Completion
2022-12-08
Completion
2023-02-02
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05445128 on ClinicalTrials.gov